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Abstract
Schistosomiasis is a neglected tropical disease that affects millions of people worldwide. 
Thioredoxin glutathione reductase of Schistosoma mansoni (SmTGR) is a validated drug target 
that plays a crucial role in the redox homeostasis of the parasite. We report the discovery of new 
chemical scaffolds against S. mansoni using a combi-QSAR approach followed by virtual 
screening of a commercial database and confirmation of top ranking compounds by in vitro 
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experimental evaluation with automated imaging of schistosomula and adult worms. We 
constructed 2D and 3D quantitative structure–activity relationship (QSAR) models using a series 
of oxadiazoles-2-oxides reported in the literature as SmTGR inhibitors and combined the best 
models in a consensus QSAR model. This model was used for a virtual screening of Hit2Lead set 
of ChemBridge database and allowed the identification of ten new potential SmTGR inhibitors. 
Further experimental testing on both shistosomula and adult worms showed that 4-nitro-3,5-bis(1-
nitro-1H-pyrazol-4-yl)-1H-pyrazole (LabMol-17) and 3-nitro-4-{[(4-nitro-1,2,5-oxadiazol-3-
yl)oxy]methyl}-1,2,5-oxadiazole (LabMol-19), two compounds representing new chemical 
scaffolds, have high activity in both systems. These compounds will be the subjects for additional 
testing and, if necessary, modification to serve as new schistosomicidal agents.
1. Introduction
Schistosomiasis is one of the major neglected tropical diseases (NTDs) that affects millions 
of people worldwide.1 Recent estimates suggest that at least 261 million people required 
preventive treatment for this disease in 2013. This parasitosis is reported in 78 countries 
located in sub-Saharan Africa, the Middle East, the Caribbean, and South America, resulting 
in 20,000 to 200,000 deaths annually.2 The disease is caused by flatworms of the genus 
Schistosoma (S. mansoni, S. japonicum, S. haematobium, S. intercalatum, and S. 
mekongi).3, 4 In the absence of a vaccine, praziquantel (PZQ) has been the drug of choice 
recommended by the World Health Organization for the treatment and control of all the 
major Schistosoma species in mass drug administration programs for almost three decades.5 
However, the disseminated and repeated use of this drug in endemic areas, because of the 
high incidence of reinfection, brings concerns about the development of parasitic 
resistance.6, 7 This problem is further emphasized by the known lack of efficacy of PZQ 
against juvenile worms,8 which is a potential cause of treatment failure in endemic areas. 
For these reasons, the development of new schistosomicidal drugs is urgently required.6–10
The complete genome sequencing of S. mansoni has brought the possibility of exploring a 
great variety of biological targets in the search for new drugs against this parasite.11, 12 
Thioredoxin glutathione reductase of S. mansoni (SmTGR, E.C. 1.8.1.9) plays a crucial role 
in the redox homeostasis of the parasite.13 SmTGR is a multifunctional enzyme that acts in 
the detoxification of reactive oxygen species (ROS) present in the blood vessels of the 
mammalian host, thus allowing parasite survival. While mammalian cells use several 
enzymes of the glutathione and thioredoxin systems, S. mansoni ROS detoxification relies 
only on SmTGR. 13, 14 Moreover, it has been validated as a potential drug target as 
demonstrated in studies silencing SmTGR expression using RNA interference.13 Validation 
studies have also been performed in S. japonicum, confirming the importance of TGR in 
parasite survival.15, 16
Advances in computational hardware and software over the last few decades have enabled 
the development of new strategies for computer-aided/assisted drug design (CADD), which 
has the advantages of reducing the time and costs in the identification of new drug 
candidates.17–23 Quantitative structure-activity relationship (QSAR) has been widely-used as 
a lead optimization tools as well as for pharmacokinetics property optimization and in 
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virtual screening campaigns.24, 25 Our group has been working on developing and applying 
many CADD strategies aiming at discovering new drug candidates for neglected tropical 
diseases. In this context, different QSAR methods have been applied for identification of 
new hits for these diseases.26–28 Another important technological advance impacting drug 
discovery was the introduction of automated microscopes along with powerful image 
analysis software enabling high-throughput phenotypic assays of cells and small organisms, 
a technique known as high-content screening (HCS), imaging (HCI) or analysis (HCA).29 
Whole-organism antihelminthic screens employing the HCS approach have already proved 
useful for the larval stage of S. mansoni.30
The goal of this study was the identification of novel anti-schistosomal agents, preferably 
representing new chemical scaffolds. To achieve this goal, we used combi-QSAR approach, 
uniting 2D and 3D QSAR models, followed by virtual screening of Hit2Lead chemical 
library and experimental evaluation of the potential SmTGR inhibitors against schistosomula 
and adult lifecycle stages of S. mansoni. For the latter test, novel medium-throughput assay 
methodology using 96-well microplate and HCI technology is implemented.
2. Methods
All critical steps of the study are summarized in the workflow presented in Figure 1. Our 
workflow followed the best practices of QSAR modeling and computer-assisted molecular 
design.21, 31 The main steps of the workflow are the following: (i) data curation; (ii) models 
building; (iii) virtual screening; and (iv) experimental validation of suggested/designed hits.
Dataset
The QSAR studies were performed using a series of 35 oxadiazoles-2-oxides reported in the 
literature as inhibitors of SmTGR. Theirs in vitro enzymatic potency values (measured by 
IC50) were obtained by the same experimental protocol.32, 33 The molecules were drawn 
manually and resulting chemical structures as well as associated activity values were verified 
following our standard curation protocols.34, 35 Then the IC50 values were converted to 
negative logarithmic units, pIC50 (−log IC50) with approximate range of three orders of 
magnitude. The dataset was manually divided into training and external test sets, ensuring a 
representative coverage across the entire range of pIC50 values. Curated chemical structures 
and corresponding IC50 and pIC50 values are listed in Table 1.
The 3D structures of compounds were generated using OMEGA software v.2.5.1.4.36, 37 
OMEGA generates various initial conformations for each compound based on a database of 
pre-calculated fragments and the structures are optimized by MMFF94 force field. All 
QSAR models were generated and analyzed using SYBYL-X software v.1.2.38
HQSAR
The HQSAR module available at SYBYL-X software v.1.2 38 was used for generation of 
HQSAR models. The models were derived using the standard fragment size (4–7 atoms) and 
various combinations of fragment distinctions. Only the models with q2LOO > 0.5 were 
chosen for external validation.
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HQSAR models were obtained using combinations of different fragment distinctions (A, 
atoms; B, bonds; C, connectivity; H, hydrogen; DA, donor and acceptors of hydrogen 
bonds), fragment size (2–5, 3–6, 4–7, 5–8, 6–9, 7–10 atoms), and hologram length (53–401).
Atomic charges assignment
Two different charge assignment methods were used, the empirical method Gasteiger-
Hückel,39, 40 available at SYBYL-X v.1.2 platform 38 and the semi-empirical AM1-BCC 
charges 41, 42 available at QUACPAC software v.1.6.3.143
Molecular alignment
The shape-based alignment and alignment based on a morphological similarity function 
were evaluated. The former was performed using ROCS software v.3.2.1.4.44, 45 First, 
several conformers were calculated for each molecule in OMEGA v.2.5.1.4,36, 37 which 
generated various initial conformations obtained from a database of pre-calculated 
fragments. Then, the conformers were superimposed, using ROCS, with the most potent 
SmTGR inhibitor (33). The conformers were classified according to the TanimotoCombo 
score function.45 The alignment based on morphological similarity function was done in 
Surflex-Sim, available at SYBYL-X v.1.2.38 Two most potent SmTGR inhibitors, 
compounds 24 and 33, were chosen for template definition. Remaining compounds were 
superimposed with this template. The maximal number of poses generated per molecule was 
20. The best pose of each compound was chosen based on the calculated similarity to the 
template.
CoMFA
The aligned training set molecules were placed in a 3D lattice box, with a grid spacing of 
0.5, 1.0, 1.5 and 2.0 Å in the x, y, and z directions. CoMFA steric and electrostatic fields 
were calculated at each grid point with the Tripos force field using a carbon atom probe with 
sp3 hybridization (Csp3) and charge +1.0. The energy cutoff was set to 30 kcal/mol. The 
standard deviation coefficients (SDC) were used for region focusing, with values ranging 
from 0.3 to 1.5.
CoMSIA
CoMSIA models were generated using the same molecular alignments used for CoMFA. 
The aligned compounds were placed in a 3D lattice box, with a grid spacing of 2.0 Å. In 
addition to the steric and electrostatic fields, hydrophobic, hydrogen bond donor and 
acceptor descriptors were included in CoMSIA studies. A probe carbon atom with radius of 
1.0 Å and charge +1.0 was used for obtaining the similarity indices. A Gaussian function 
was used to describe the energetic terms in function of the distance between the probe atom 
and the aligned molecules with an attenuation factor of 0.3.
QSAR models building and validation
Partial least squares regression (PLS)46–48 was used for development of statistical models 
for all 3 descriptors sets. The internal validation of the QSAR models was performed using 
the full cross-validation r2 (q2), leave-one-out (LOO), and leave-many-out (LMO) methods. 
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The latter was used to evaluate the stability of the best models and was performed using five 
groups and 25 runs. The predictive ability of the models was assessed by Q2ext estimated on 
external set compounds that were not used for model building or selection. Four consensus 
models were generated using different combinations of the best individual HQSAR, 
CoMFA, and CoMSIA models. Three consensus models were obtained by pairwise 
combinations of individual models (HQSAR+CoMFA, HQSAR+CoMSIA, and CoMFA
+CoMSIA) and one model was obtained by combination of three models (HQSAR+CoMFA
+CoMSIA). The combination did not occur during models building. The models were built 
and used separately for predictions. The predicted activity of each compound by a consensus 
model was the result of the arithmetic mean of individual models predictions. The external 
validation of these models was done using the same metrics as for individual models.
Virtual screening of new potential Sm TGR inhibitors
The virtual screening of potential SmTGR inhibitors was performed based on similarity and 
common substructure search in the Hit2Lead chemical library from ChemBridge database.49 
First, the most potent inhibitor of the dataset (33) was used as a template for the similarity 
search. The molecular access system (MACCS) structural key fingerprints50–52 were 
calculated for compound 33 and molecules from Hit2Lead chemical library. Subsequently, 
Tanimoto coefficient was calculated between compound 33 and compounds from database. 
Compounds with Tanimoto coefficient (Tc ≥ 0.6) were selected. Additionally, the 
substructure search was applied to find compounds containing the common substructure, 
i.e., the oxadiazole ring. All compounds were prepared using the same protocol and software 
used in QSAR dataset preparation, i.e., 3D structure and conformer generation, partial 
atomic charges calculation and molecular alignment. The chosen method of alignment and 
partial charges calculation was the same of the best individual CoMFA and CoMSIA 
models. In the next step, the best consensus model was used to predict the biological activity 
of the potential SmTGR inhibitors. The most promising compounds, with highest predicted 
pIC50, were selected for biological evaluation. Furthermore, five highly-predictive in-house 
models, described elsewhere,53, 54 were used to predict some ADME properties of the 
compounds, such as logP, Caco-2 cell permeability, blood-brain barrier penetration (BBBP), 
hERG inhibition, CYP3A4 inhibition, and water solubility.
Biological evaluation on S. mansoni
Compounds and Media—Ten selected compounds were purchased from ChemBridge 
(San Diego-CA, USA) and given the identifiers LabMol-13 to LabMol-22. Compounds were 
resuspended in 100% DMSO and used immediately in the assays. DMEM and M169 media 
were purchased from Vitrocell (Campinas, SP, Brazil). All other reagents were purchased 
from Sigma-Aldrich (St. Louis, MO, USA).
Larval Schistosoma mansoni (schistosomula) in vitro assay—Schistosomula 
were produced by the mechanical method adapted from both Mansour et al. (2010) 55 and 
Marxer et al. (2012).56 The cercariae (S. mansoni, BH strain) were vortexed at maximum 
speed for 5 minutes for tail shedding and cercariae transformation into schistosomula. The 
schistosomula were resuspended in Medium 169, plated in 384 well plates (120 per well) 
and maintained in an incubator with 5% CO2 overnight before compound addition. 
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Schistosomula were divided into three groups: negative control (0.625% DMSO), positive 
control (10 µM of PZQ or Oltipraz (OLT)), and treated (LabMol compounds at a 
concentration range of 0.3125-20 µM). The effect of the compounds on schistosomula 
motility and phenotypes was assessed at 48h after compound addition using an automated 
analysis method described below.
Automated scoring of schistosomula motility and phenotype—The automated 
image-based method for scoring schistosomula motility and phenotype was performed as 
described previously.57 Bright-field images were collected using an ImageXpressMicro HCS 
microscope (IXM; Molecular Devices, Wokingham, UK). For motility analysis 5 × 6 sec 
interval time-lapse images were collected using a 4x objective. For detailed morphology a 
10x objective was used to collect 4 adjacent images fields from within a well, which were 
considered together to maximize larval numbers for phenotype analysis. Analysis of both the 
larval phenotype and motility was then carried out in Pipeline Pilot 9 as described by 
Paveley et al. (2012).57 Phenotype analysis of individual parasites was carried out by a two 
class Laplacian-modified Bayesian categorization model analysis of 80 image descriptors 
which constituted shape, size, image intensity, and texture statistics and compared to a 
training set of data comprising 20,000 parasites. Motility analysis of individual parasites was 
also done by the average object displacement from the origin point in subsequent 4x image 
across the time-frame series. Both the Bayesian phenotype and motility scores are 
subsequently adjusted to the control wells (DMSO treated) on each plate.57
Adult Schistosoma mansoni ex vivo assays—Three- to six-days-old Swiss mice 
were individually infected percutaneously with 150 ± 10 S. mansoni cercariae (BH strain). 
The animals were placed into cylindrical vials under incandescent light with a thin water 
layer containing the cercariae for a period of 30 min. At 42–49 days after infection (i.e., the 
time required for S. mansoni to reach maturity), the animals were euthanized, and the worms 
were perfused (with 0.85% sodium chloride and 0.75% sodium citrate solution) from 
mesenteric and portal hepatic veins. Worms were rinsed and individually transferred into 96 
well plates with complete DMEM media (i.e., DMEM plus 10% fetal calf serum, 2mM L-
glutamine, 100 µM/ml penicillin, 100 µg/ml streptomycin). Male and female worms were 
distributed in three groups of six individuals each: negative control (0.02% DMSO), positive 
control (10 µM PZQ) and treatment (10 µM LabMol compounds). The plates were 
maintained at 37 °C in a humidified atmosphere of 5% CO2 throughout the entire 
experiment. The effect of the compounds on adult worm motility was assessed either 
immediately or 24, 48, or 72h after compound addition using the automated analysis method 
(see below).
Automated measurement of adult worm mobility—Our strategy was based on 
sequential pairwise comparison of 100 time-lapse images captured every 250–300 ms using 
an automated bright-field microscope with a 2x objective lens (ImageXpress Micro XLS, 
Molecular Devices, CA). Subsequent quantitative image analysis used a custom-developed 
pipeline for detecting changes in parasite motility using the open-source CellProfiler 
software version 2.1.2.58 The pipeline along with its validation will be thoroughly described 
in a subsequent publication and the pipeline itself will be made freely available. Briefly, at 
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each cycle of the pipeline, an image captured at a given instant (tn) is compared with the 
image captured at the preceding instant (tn-1) and so on until all images are processed. Two 
different motility measurements were calculated. First, a precursor metric, 
“AdjustedRandIndex” is calculated by comparing worm objects identified on images 
captured at times tn and tn-1 with CellProfiler’s Overlap module. This measure ranges from 0 
to 1, with 1 meaning two objects are perfectly aligned (no movement). Hence, we created an 
“Overlap” mobility score, which is directly proportional to the amount of movement, by 
subtracting 1-”AdjustedRandIndex”. Another motility measure, “DiffWorms”, is the mean 
pixel intensity of the image calculated from the absolute difference of the parasite images in 
tn-1 and tn. The higher the DiffWorms score higher is the parasite mobility measured. Both 
measures are iteratively taken for the 99 image pairs and scores per well are calculated by 
averaging over all measurements.
Statistical Analysis of biological evaluation—All statistical analysis and graphs were 
performed using GraphPad Prism version 5.00 for Windows (GraphPad Software, La Jolla, 
CA, USA, www.graphpad.com).
Ethics statement—Animals were maintained and experiments carried out in accordance 
with the Institutional Ethics Committee for Laboratory Animal Use at the Oswaldo Cruz 
Foundation (CEUA/FIOCRUZ, Brazil; license number, LW-78/12) or using the NC3Rs and 
ARRIVE guidelines under the United Kingdom Animal’s Scientific Procedures Act 1986 
with approval from the London School of Hygiene and Tropical Medicine Ethics committee.
Molecular Docking
The structure of SmTGR was obtained from Protein Data Bank59(PDB ID: 2×8H, resolution 
of 1.9 Å).60 The structure was imported to Maestro v. 10.0 61 and prepared using Protein 
Preparation Wizard workflow as follows: hydrogen atoms were added according to Epik v. 
2.7 62, 63 (pH 7.4 ± 0.5) and minimized using the OPLS-2005 force field.64 Then the 
structures of compounds to be docked were drawn on MarvinSketch65 and a maximal of 
2,000 conformations was generated using OMEGA v.2.5.1.4.36 Subsequently, the 
conformers had their most favorable ionization state calculated at pH 7.4, using ‘fixpka’ 
function available on QUACPAC v.1.6.3.1.43 Additionally, AM1-BCC charges were added 
using QUACPAC v.1.6.3.1.43 Prior to docking studies, two different grids were defined: one 
for the thioredoxin domain (Trx) and another for glutaredoxin domain (Grx). The Trx grid 
was built with dimensions of 30.73 Å × 19.18 Å × 19.61 Å (x, y and z) and volume of 
11,562 Å3. The Grx grid had dimensions of 19.89 Å × 14.89 Å × 13.61 Å (x, y and z) and 
volume of 4,029 Å3. Finally, molecular docking of selected compounds was performed in 
FRED, available in OEDocking suite v. 3.0.166, using the high resolution precision and 
ChemGauss4 scoring function. In addition, a covalent docking was performed on the 
package Prime v.3.8.67, 68 Prior to covalent docking, the ligands were prepared on LigPrep69 
using OPLS-2015 force field64 and Epik v. 2.7 62, 63 (pH 7.4 ± 0.5).
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3. Results and Discussion
QSAR models
Hologram length and fragment size and distinction can affect the quality of HQSAR 
models.46, 70 In this work, various combinations of these parameters were tested. The final 
HQSAR models were obtained using combinations of different fragment distinctions (A, 
atoms; B, bonds; C, connectivity; H, hydrogen; DA, donor and acceptors of hydrogen 
bonds), fragment size (2–5, 3–6, 4–7, 5–8, 6–9, 7–10 atoms) and hologram length (53–401).
Three best HQSAR models are presented in Table S1 (Supporting Information). They have 
similar statistical characteristics but model 2 showed a slight superiority when evaluated the 
external set. The best HQSAR model was obtained using the fragment distinction A/DA 
(Table 2). The predicted activity (pIC50) for the test set compounds using this model (Table 
S2, Supporting Information) indicated that only two compounds had their predicted values 
greater than the standard deviation of residuals, indicating a good predictive capacity of the 
model. The plot of the experimental versus predicted biological activity of the best HQSAR 
model is displayed in Supporting Information (Figure S1A).
Besides predicting the biological activity of untested compounds, HQSAR models also give 
information regarding the relationships between the structural fragments and the biological 
activity, which can be visualized through the contribution maps. These maps indicate the 
individual contribution of each atom or fragment for the activity by color-coded schemes. 
Colors around red spectrum (orange, red orange, and red) indicate negative contribution, 
while colors around green (yellow, green blue, and green) indicate positive contribution to 
biological activity. The contribution maps for the most (33) and the less (2) potent 
compounds of our data set are presented in Figure 2.
The contribution map for the most potent inhibitor of the dataset (33, Figure 2) suggests that 
the oxygen atom (O11) from carbonyl group has positive contribution for the biological 
activity. Moreover, the furan ring is important for the biological activity since the O17 has a 
positive contribution for activity. The carbon atoms C10, C13, and C14 also have positive 
contribution to the biological activity. Despite the fragments in green and yellow, the 
contribution map for the less potent inhibitor (2) suggests that the hydrogen atom attached to 
the carbon atom C12 negatively contribute to biological activity. The absence of the two 
carbonyl groups and furan rings in compound 2 suggests that these groups may play a 
critical role in SmTGR inhibition, because the activity decreased three logarithmic units in 
comparison to compound 33.
Previous study carried out by Gasco and co-workers 71 indicated that the oxadiazoles are 
capable of releasing nitric oxide in solution containing thiols by nucleophilic attack in C3 
and C4 carbon atoms. Because SmTGR has a selenocysteine (Sec) residue in the C-terminal 
end, the oxadiazoles may undergo nucleophilic attack mainly by this residue due to its 
superior reactivity in comparison to cysteine. The resulting nitric oxide release may be the 
reason for the antiparasitic activity described for these compounds.32 The presence of the 
carbonyl group in the most potent inhibitors of the dataset suggests an important role of this 
group, which behaves as a linker that favors the nucleophilic attack in C3 and C4 atoms.
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In CoMFA and CoMSIA studies, the calculation of electrostatic descriptors depends on the 
assignment of partial atomic charges of the compounds. Therefore, the charge assignment 
method is critical to the success and may affect the quality of the developed models.26 
Furthermore, the contour maps may have some differences depending on the method used 
for partial atomic charges assignment.72, 73 Two different charge assignment methods were 
tested in this study, the empirical method Gasteiger-Hückel,39, 40 and the semi-empirical 
AM1-BCC charges.41, 42
Another crucial aspect in 3D-QSAR studies is the structural alignment, which is used to 
represent the probable bioactive conformation of the compounds. The quality of the 3D-
QSAR models can be directly affected by the structural alignment.74 Therefore, two ligand-
based alignment hypotheses were tested, the shape-based alignment using ROCS software v.
3.2.1.444, 45 and the morphological similarity alignment, implemented in Surflex-Sim, 
available at SYBYL-X v.1.2 platform.38 The data set was aligned using the two schemes, 
displayed in Figure 3. In alignment 1, the best conformer of each molecule, after 
superposition, was classified according to TanimotoCombo score function. TanimotoCombo 
is a combination of the functions ShapeTanimoto, which compares the molecules according 
to the best molecular volume superposition, and ColorTanimoto which is related to the 
appropriate superposition of groups with certain properties like hydrogen bond donors and 
acceptors, hydrophobic, cations, anions, and rings.45 In alignment 2, no previous conformers 
were generated since Surflex-Sim has fast techniques to generate poses. Additionally, a 
morphological similarity function is used to align the molecules. This function is defined as 
a Gaussian function of the distances of two molecules to observation points of a grid.75
In 3D-QSAR, similarly to HQSAR, compounds 4 and 6 were identified as outliers, the same 
identified in HQSAR modeling. The outlier detection was performed using a CoMFA model 
generated with all compounds of the dataset and default grid spacing of 2.0 Å. The 
compounds 4 and 6 were identified as outliers, since their calculated residues were near or 
higher than two times the standard deviation of residues.
CoMFA and CoMSIA models were investigated by PLS analysis, using the full cross-
validated r2 (q2) leave-one-out (LOO) method. The leave-many-out (LMO) method was used 
to evaluate the stability of the best models. To evaluate the 3D-QSAR models predictive 
power, we used Q2ext. The full results of the best CoMFA and CoMSIA models are 
displayed in Supporting Information (Tables S3 and S4, respectively).
Two best CoMFA models presented good internal consistence and high external predictivity 
(Table 2). The models generated using the AM1-BCC charges and ROCS alignment (Models 
I and II) showed superior performance in comparison with those generated using Gasteiger-
Hückel charges and Surflex-Sim alignment (Table 2 and Table S3, Supporting Information).
The best CoMSIA models were obtained using the steric, electrostatic, hydrophobic, and H-
bond acceptor fields (Table S4, Supporting Information). The two best CoMSIA models 
were obtained using ROCS alignment, one using Gasteiger-Hückel charges (Model I, Table 
2) and the other using AM1-BCC charges (Model II, Table 2). These two models have 
similar results for internal validation and external predictivity. The difference between the 
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two best CoMSIA models can be better visualized in the prediction of the activity of test set 
compounds (Table S2, Supporting Information). Observed versus predicted activities for 
both training and test sets are displayed in Figure S1B and S1C (Supporting Information).
The best CoMFA and CoMSIA models were used to generate contour maps. These maps 
indicate regions where certain types of interactions are favorable or unfavorable for 
biological activity.76 The interpretation of contour maps is useful to guide the design of new 
potent inhibitors of SmTGR. CoMFA and CoMSIA contour maps were generated using the 
STDEV*COEFF field type and the function Contour by actual. Figure 4 shows contour 
maps obtained from (A) CoMFA steric (green/yellow) and (B) electrostatic (red/blue) fields; 
(C–F) CoMSIA steric (green/yellow), electrostatic (red/blue), hydrophobic (yellow/gray) 
and hydrogen bond acceptor (purple/magenta) fields with the most potent compound of the 
data set (33).
The steric contour map of the best CoMFA model (Figure 4A) shows green contours 
surrounding the furan ring of the compound (33), indicating that bulky substituents could be 
favorable to biological activity. Figure 4B shows red regions near the oxygen atoms O12 and 
O11 of the carbonyl groups, where substitution for electronegative groups can favor the 
biological activity. Furthermore, this map shows blue regions surrounding the carbon atoms 
of the furan rings, indicating that electronegative substituents at the furan rings are 
unfavorable. This map indicates that the carbonyl group represented by C7 and O12 atoms is 
important for biological activity. For the CoMFA and CoMSIA models, steric and 
electrostatic contribution maps were similar. The steric contour map of the best CoMSIA 
(Figure 4C) model also indicates that bulky groups in the region near the furan ring are 
favorable to biological activity. The electrostatic map (Figure 4D) indicates that 
electronegative groups in the region of the oxygen atoms of the carbonyl groups (O12 and 
O11) are favorable. Furthermore, electropositive groups in the region near the carbon atom 
C7 are favorable. In addition, the electrostatic CoMSIA map indicates that electronegative 
groups near the oxygen atom O17 of the furan ring are favorable to biological activity. The 
hydrophobic contour map (Figure 4E) shows two gray contours near the oxygen atoms of 
the carbonyl groups (O12 and O11), indicating that hydrophobic groups are unfavorable in 
this region. Figure 4F shows a purple region near the oxygen atoms of the carbonyl groups 
(O12 and O11), suggesting that hydrogen bond acceptors groups in this region are favorable, 
whereas in regions near the two furan rings there are magenta contours, indicating that 
substitution for hydrogen bond acceptors is unfavorable to biological activity.
Four different consensus models were obtained using different combinations of the best 2D- 
and 3D-QSAR models (Table 3). The external validation of consensus models was 
performed using the same test set and metrics used in individual models. Model 4 (Table 3) 
was selected as the best consensus model because it had good performance and unites the 
characteristics of the three QSAR approaches explored.
Virtual screening
The best consensus model was used to activity prediction after a virtual screening of new 
potential SmTGR inhibitors. Firstly, a similarity search on the Hit2Lead library of 
ChemBridge database49 identified 80 compounds with TC≥0.6 with compound 33. 
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Additionally, 377 compounds containing the oxadiazole ring (common substructure) were 
identified. Duplicates including compounds already used to derive the QSAR models were 
excluded. Then, model 4 was used to predict the SmTGR inhibitory activity of remaining 
194 compounds. The consensus prediction of the biological activity was calculated using the 
arithmetic mean of the predictions from individual HQSAR, CoMFA, and CoMSIA models 
(Table S5, Supporting Information).
The use of similarity search in virtual screening is an example of computational approach for 
identification of new chemical scaffolds, as described elsewhere.77, 78 In the review by 
Heikamp & Bajorath78, the use of molecular fingerprints is highlighted as an important way 
to search novel active compounds. Other examples of approaches for scaffold hopping are 
shape matching, 3D pharmacophore searching and fragment replacement.77 In a study 
performed by Gardiner and coworkers, the use of 2D fingerprint similarity has proven to be 
a simple and efficient way to perform the search of new chemical scaffolds. In their study, 
they evaluated the effectiveness of six different types of 2D fingerprints for scaffold hopping 
in three different databases.79 Several successful examples of drug design by scaffold 
hopping approaches are also described elsewhere.80
Poor pharmacokinetic properties are important causes of costly late-stage failures in drug 
development.81 Our laboratory has been working to overcome or reduce these failures using 
in silico tools for early prediction and optimization of ADME properties, such as Caco-2 cell 
permeability, blood-brain barrier penetration (BBBP), hERG inhibition, CYP3A4 inhibition 
and water solubility. Five in-house highly-predictive models were developed using large 
datasets of diverse compounds to cover the chemical space for the prediction of new 
compounds and are described elsewhere.53, 54 Table 4 shows the structure, consensus 
predicted potency against SmTGR (IC50 in µM), and some predicted ADME properties of 
the ten new potential SmTGR inhibitors.
As we can see from Table 4, ten compounds selected as virtual hits presented high predicted 
potency against SmTGR, using the consensus QSAR model. Moreover, the selected hits 
were predicted to present favorable ADME properties and did not show any potential of 
being hERG blocker or CYP3A4 inhibitors. These compounds were selected for subsequent 
in vitro biological evaluation against schistosomula and adult S. mansoni worms.
Biological evaluation on S. mansoni
The whole-organism screening (phenotypic screening) is an indispensable method to 
identify new anti-schistosomal compounds. In our study, despite the prediction of 
compounds as potential SmTGR inhibitors, it was necessary to evaluate their activity in a 
phenotypic screening. A promising anti-schistosomal compound, to reach the target, must be 
able to cross many biological membranes and resist degradation by enzymes of the parasite. 
Thus, a hit identified in early phenotypic screening has more biological relevance than one 
identified in an enzyme inhibition assay. Two out of ten tested compounds (LabMol-17 and 
LabMol-19) were confirmed experimentally as new hits against Schistosoma mansoni.
Motility and phenotypic scores of LabMol-17 and LabMol-19 at 10 µM along with the 
negative (DMSO 0.625%) and positive controls (PZQ or OLT 10 µM) are shown in Table 5. 
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The phenotypic and mobility scores calculated by the Bayesian model for both hits indicate 
their effects on schistosomula are equivalent or even more pronounced than produced by the 
reference drugs PZQ and OLT. EC50 values could be calculated from dose-response curves 
using either motility score (LabMol-19 EC50 1.00 ± 0.11 µM) or phenotype score as the 
response (LabMol-17 EC50 4.76 ± 1.15 µM). The motility EC50 value determined for 
LabMol-19 was comparable to PZQ (EC50: 2.2 µM).82
Furthermore, the Bayesian model was able to classify the phenotype induced by both hit 
compounds as OLT-like indicating that the phenotype induced by these compounds was 
closest to OLT in comparison to the other modeled schistosomacides (PZQ, 
dihydroartemisinin, methylclonazepam, Ro15-5458, and oxamniquine). This result is 
consistent with the fact that both LabMol-17 and LabMol-19 are potential inhibitors of 
SmTGR, an enzyme involved in ROS detoxification in the S. mansoni, similar to the OLT 
mechanism of action which is also thought to interfere with the parasite’s redox defense 
system.83
Compounds active on schistosomula were then tested on S. mansoni adult worms in vitro. 
Chemicals were assayed by a new methodology that utilizes HCS technology to 
automatically score changes on parasite motility. Besides avoiding human bias, this 
quantitative method is more robust and sensitive to subtle changes in parasite movement 
than the standard assay using manual microscopic visualization.84 Figures 5 and 6 shows 
percent motilities of male and female worms, respectively, measured after exposure to drugs 
at 10 µM for up to 72h incubation time.
Like PZQ, both LabMol-17 and LabMol-19 were more active on male worms. LabMol-17 
was the most active hit, reducing male worm motility up to five times compared to untreated 
control worms. Significant reduction (p<0.05) of male worm motility was observed 
immediately after addition of the drugs to the microplate well and in the case of LabMol-17 
peaked after 48h incubation. Effects on female worms were less pronounced. A discernible, 
although not statistically significant, trend could still be observed for LabMol-17 after 24 h 
and 48 h of drug exposure. Interestingly, although not statistically significant for the whole 
treatment group, LabMol-19 induced augmented motility in at least half of the female 
worms in the group on exposure times up to 48h. Further experiments will elucidate if this 
different behavior on drug sensitivity between male and female worms may be due to 
different expression patterns of SmTGR or other reasons.
Both experimentally validated hits, LabMol-17 and LabMol-19, are dissimilar from the most 
potent compound (33) in the training set (Tc of 0.60 and 0.63, respectively, see Table S5, 
Supporting Information). Moreover, the most active hit, LabMol-17, is very dissimilar from 
the current schistosomicidal drug, PZQ (Tc = 0.07) and oltipraz (Tc = 0.08), as well as from 
other known antischistosomal drugs (Figure 7).
Moreover, we have also analyzed the similarity between LabMol-17 and LabMol-19 and 
known SmTGR hits discovered in a HTS screening (PubChem BioAssay, AID: 485364). As 
we can see from Figure 7, LabMol-17 represents a new chemical scaffold very dissimilar 
(Tc = 0.20 – 0.47) from known drugs and active compounds against S. mansoni. The 
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situation with LabMol-19 is pretty much the same (Tc = 0.24 – 0.38). High activity against 
schistosomula and adult worms of LabMol-17 and LabMol-19 made them promising 
potential SmTGR inhibitors representing novel not yet explored chemical scaffolds highly 
dissimilar with known anti-schistosomal drugs.
Molecular docking
The two hits identified in this study were docked in two important catalytic domains of 
SmTGR: (i) Trx domain where reducing equivalents are transferred from reduced FAD to 
the Cys154-Cys159 pair and (ii) the Grx domain, which contains the Cys28-Cys31 pair and 
receives reducing equivalents from the highly mobile C-terminal end. The C-terminal end, 
which has cysteine and a selenocysteine residues (Cys596-Sec597 pair) was not used for 
docking for two reasons: (i) The C-terminal end is missing in the structure from PDB (ID: 
2X8H); and (ii) The PDB structure containing the C-terminal end (ID: 2X8C) has low 
quality in terms of resolution (3.1 Å).
Two different docking methods were used: a conventional docking for evaluation of 
molecular interactions and a covalent docking. Figure 8 shows the interactions, after 
conventional docking, between the hits and SmTGR. It can be observed that both 
compounds establish important interactions in both domains of SmTGR. The ChemGauss4 
score of LabMol-17 and LabMol-19, in Grx domain (Figure 8A and 8C), was −3.292 and 
−3.802 kcal/mol, respectively. However, the scores were better in Trx domain, −9.569 and 
−8.209 kcal/mol, respectively. It suggests a possible higher affinity of these hits to the Trx 
domain. Furthermore, the binding modes of these ligands, near to cysteine residues, suggest 
the possibility of nucleophilic attacks from these residues and formation of covalent bonds.
The covalent docking was performed because SmTGR has, in both domains, a pair of 
cysteine residues which have important role in the catalytic process. Cysteine residues are 
nucleophiles and, as demonstrated in previous studies, some SmTGR inhibitors including 
the oxadizole-2-oxides, can undergo nucleophilic attack by cysteines and bind covalently in 
these residues. As result, these compounds release nitric oxide, an anti-parasitic molecule.32 
Figure 9 shows the interactions between the two hits and SmTGR after covalent docking. In 
addition to covalent bond, the hydrogen bonds between the compounds and residues seem to 
be important to the inhibition mechanism, helping the ligands to be placed in favorable 
positions to undergo nucleophilic attack and form a covalent bond with cysteine. These 
results suggest that these compounds have potential to be irreversible inhibitors of SmTGR.
One of the future directions of our study is the addition of LabMol-17 and LabMol-19, after 
their testing in enzymatic assay against SmTGR, into training set of next generation of 
models. This will provide new structural information and will increase AD of QSAR 
models. Although the introduction of new scaffolds will not affect HQSAR because of 
fragment-based nature of the approach, it will strongly influence the superposition of 
compounds in CoMFA and CoMSIA. This limitation was discussed in the original 
publication85 and was resolved in the follow-up publication.86 However, when the dataset 
consists of various scaffolds, we would recommend to use fragment-based approaches like 
HQSAR70, SiRMS87, etc.
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4. Conclusions
We succeed to develop robust and externally predictive consensus model merging 2D 
(HQSAR) and 3D (CoMFA and CoMSIA) QSAR models for SmTGR inhibition. We 
applied this model for virtual screening of Hit2Lead library of ChemBridge database and 
identified ten new potential SmTGR inhibitors. The ten virtual hits were tested against S. 
mansoni on both schistosomula and adult worms in vitro. Two of them, LabMol-17 and 
LabMol-19, showed high activity, represent new chemical scaffolds and are highly dissimilar 
(Tc = 0.20 – 0.47) with known anti-schistosomal drugs. As a future direction, we will 
perform structural modification of discovered scaffolds (compounds) to improve their 
properties and develop on their base new schistosomicidal agents.
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Figure 1. 
General workflow of our study.
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Figure 2. 
HQSAR contribution maps for the most (A, 33) and less (B, 2) potent SmTGR inhibitors. 
The 1,2,5-oxadiazole ring is highlighted in blue, which is the maximal common 
substructure.
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Figure 3. 
Molecular alignment used in 3D-QSAR studies. (A) Shape-based alignment performed in 
ROCS; (B) Surflex-Sim alignment which uses a morphological similarity function.
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Figure 4. 
CoMFA steric and electrostatic (A–B) and CoMSIA steric, electrostatic, hydrophobic, and 
H-bond acceptor (C–F) contour maps surrounding the most potent inhibitor (33). Steric 
fields: green contours indicate region where bulky groups are favorable for biological 
activity; electrostatic fields: red contours indicate regions where electronegative groups are 
favorable to biological activity and blue contours indicate regions where electronegative 
groups are unfavorable; Hydrophobic fields: yellow contours indicate regions where 
hydrophobic groups are favorable and gray contours indicate regions where these groups are 
unfavorable; H-bond acceptor fields: purple contours indicate regions where hydrogen bond 
acceptors are favorable for biological activity and magenta contours indicate regions where 
hydrogen bond acceptors are unfavorable.
Melo-Filho et al. Page 22
J Chem Inf Model. Author manuscript; available in PMC 2017 July 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 5. 
The effect of compounds on male adult worm motility as analyzed by HCS analysis for 0–72 
h. PZQ, LabMol-17, and LabMol-19 were screened at 10 µM and DMSO at an equivalent % 
concentration. The percentage motility values were determined immediately (A); 24 h (B); 
48 h (C); or at 72 h (D) by comparison to the average motility of the worms before 
compound addition. CTL - DMSO 0.02%, PZQ - Praziquantel. Statistical significance (* = 
p<0.05) was calculated by One-way ANOVA analysis followed by Tuckey´s post-hoc test.
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Figure 6. 
The effect of compound on female adult worm motility as analyzed by HCS analysis for 0 
−72 h. PZQ, LabMol-17, and LabMol-19 were screened at 10 µM and DMSO at an 
equivalent % concentration. The percentage motility values were determined immediately 
(A); 24 h (B); 48 h (C); or at 72 h (D) by comparison to the average motility of the worms 
before compound addition. CTL - DMSO 0.02%, PZQ - Praziquantel. Statistical 
significance (* = p<0.05) was calculated by One-way ANOVA analysis followed by Tuckey
´s post-hoc test.
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Figure 7. 
Radial plots for similarity of LabMol-17 with known schistosomicidal drugs and known 
SmTGR hits. The central node represents the target compound surrounded by known 
schistosomicidal drugs (left-hand side) and known SmTGR hits from a HTS screen retrieved 
from PubChem BioAssay (AID: 485364) (right-hand side). The similarity was calculated 
using Tanimoto coefficient (Tc) using MACCS structural key fingerprints.
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Figure 8. 
Interactions between the two hits and SmTGR after conventional docking. The yellow 
dashed lines show important interactions of LabMol-17 with residues of Grx domain (A) 
and Trx domain (B). The interactions of LabMol-19 with Grx domain (C) and Trx domain 
(D) are also highlighted. Both compounds have established hydrogen bonds in both domains 
and the proximity of cysteines (Cys28 and Cys159) indicate the possibility of ligands to 
undergo nucleophilic attack by these residues.
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Figure 9. 
Interactions between the two hits and SmTGR after covalent docking. The yellow dashed 
lines show important interactions of LabMol-17 with residues of Grx domain (A) and Trx 
domain (B). The interactions of LabMol-19 with Grx domain (C) and Trx domain (D) are 
also highlighted. Both compounds have established hydrogen bonds in both domains and 
covalent bonds were formed with cysteines (Cys28 and Cys159). These results suggest an 
irreversible mechanism of inhibition of SmTGR.
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Table 2
Statistical characteristics for the best individual QSAR models obtained.
Model q2LOO q2LMO r2 N Q2ext
HQSAR 0.61 0.57 0.85 4 0.94
CoMFA-model I 0.71 0.66 0.99 6 0.90
CoMFA-model II 0.72 0.67 0.99 6 0.82
CoMSIA-model I 0.51 0.48 0.99 6 0.95
CoMSIA-model II 0.60 0.55 0.99 6 0.96
q2LOO, leave-one-out cross-validated determination coefficient; q2LMO, leave-many-out cross-validated determination correlation coefficient; 
r2, non-cross-validated determination coefficient; N, optimal number of latent variables in PLS analysis; Q2ext, determination coefficient for 
external set.
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Table 3
Statistical characteristics for the consensus QSAR models.
Model Models RMSEP Q2ext
1 HQSAR + CoMFA 0.16 0.96
2 HQSAR + CoMSIA 0.12 0.98
3 CoMFA + CoMSIA 0.18 0.95
4 HQSAR + CoMFA + CoMSIA 0.14 0.97
The best consensus model is highlighted in bold font. RMSEP, root mean square error of prediction; Q2ext, determination coefficient for external 
set.
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Table 5
Motility and phenotype adjusted index values for S. mansoni schistosomula exposed for 48h to hit compounds 
or standard drugs at 10 µM.
Compound Motility adjusted index(mean ± SD)
Phenotype
adjusted index
(mean ± SD)
Motility image Phenotype image
Control (DMSO 0.625%)
LabMol-17 −0.95 ± 0.01 −0.43 ± 0.11
LabMol-19 −0.95 ± 0.01 −0.63 ± 0.02
PZQ −0.48 ± 0.04 −0.17 ± 0.02
OLT −0.90 ± 0.04 −0.34 ± 0.07
Motility images represent the position of each parasite over 5 time points (11s interval).
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